Get startedLog in
    Picture of Sorrento Therapeutics logo

    SRNE — Sorrento Therapeutics News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro Cap
    All News

    Brief: Sorrento Says Oral SARS-CoV-2 Main Protease Inhibitor, STI-1558, Strongly Neutralizes Omicron

    Picture of Sorrento Therapeutics logoSorrento Therapeutics
    28/01/2022 14:05
    Jan 28 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * SORRENTO ANNOUNCES ITS ORAL SARS-COV-2 MAIN PROTEASE
(MPRO)
INHIBITOR, STI-1558, STRONGLY NEUTRALIZES OMICRON
    * SORRENTO THERAPEUTICS INC - STI-1558, A NOVEL ORAL MPRO
INHIBITOR, EFFECTIVELY INHIBITS OMICRON VIRUS ENTRY AND
REPLICATION IN CELLS
    * SORRENTO THERAPEUTICS INC - STI-1558'S ANTIVIRAL ACTIVITY
AGAINST OMICRON HAS ALSO BEEN TESTED IN A CELL-BASED
NEUTRALIZATION ASSAY

Source text for Eikon:  ID:nGNX3TmQNs 
Further company coverage:  SRNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))

    Recent news on Sorrento Therapeutics

    See all news